MedWatch

CEO: Genmab sustainable, profitable before 2017

Following a number of demanding years, which have led to a 70 % reduction of staff, Genmab is on the verge of becoming sustainable and profitable. The company has learned its lesson from past partnerships that proved too challenging for them, says the CEO.

Foto: Genmab/PR

A number of highly attractive partnerships with pharmaceutical giants like Johnson & Johnson, GlaxoSmithKline (GSK) and Roche, combined with annual costs of just 100m dollars, has enabled Genmab to move extremely close to becoming sustainable and profitable.

“We were already profitable in the first quarter of 2013, but when it comes to being a sustainable, profitable company, most analysts expect that to happen during 2017. We are a sustainable, profitable company when we are fully financed through our partnerships, and I think it could happen even before 2017,” CEO Jan van de Winkel says in an interview with Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier